期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Impact of clopidogrel treatment on platelet function and thrombogenecity in diabetic patients undergoing elective coronary stenting
1
作者 anand singla Kevin P. Bliden +8 位作者 Young-Hoon Jeong Joseph DiChiara Mark J. Antonino Denny P. Mathew William C. Muse Katrina Abadilla Tania Gesheff Udaya S. Tantry Paul A. Gurbel 《Journal of Diabetes Mellitus》 2012年第2期153-164,共12页
High platelet reactivity (HPR) and suboptimal response to dual antiplatelet therapy (DAPT) may explain high recurrent rates of ischemic events in Type II diabetes mellitus (DM) patients undergoing percutaneous coronar... High platelet reactivity (HPR) and suboptimal response to dual antiplatelet therapy (DAPT) may explain high recurrent rates of ischemic events in Type II diabetes mellitus (DM) patients undergoing percutaneous coronary intervention (PCI). The aim of this study was to examine the effect of clopidogrel on platelet reactivity, and thrombogenecity between DM and non-DM PCI-treated patients (n = 138). Patients were categorized according to clopidogrel treatment and DM status. Patients received a maintenance-dose clopidogrel of 75 mg/d (C75 group, n = 72) or a 600 mg clopidogrel loading-dose in clopidogrel na?ve patients (C600 group, n = 66). Platelet function was assessed by thrombelastography, flow cytometry, VerifyNowTM aspirin assay and light transmittance aggregometry (LTA). Aspirin response was similar between treatments and DM status. In the C75 group, DM patients had higher 5 and 20 μM ADP-, 2 μg/ml collagen-induced LTA;and p-selectin expression compared to non-DM patients (p ≤ 0.05 for all). DM patients in the C600 group had higher 5 and 20 μM ADP-induced LTA post dosing (p p 12 receptor antagonists. 展开更多
关键词 Diabetes CLOPIDOGREL PLATELET REACTIVITY HYPERCOAGULABILITY
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部